ArticleJBMR plus2025
Direct and indirect effects of transforming growth factor-beta on osteoclast-mediated bone remodeling using a new in vitro bone matrix model.
Article in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Osteogenic differentiation of gingival and periodontal ligament fibroblasts inhibits osteoclast formation in 2D and 3D fibrin cultures.Bone reports · 2026Article
- From Bone Marrow Reserve to Metastatic Niche: How Neutrophil-Lineage Cells Shape Skeletal Colonization.International journal of molecular sciences · 2026Review
- Orthobiologics in Trauma: Current Trends, Future Directions, and Regenerative Strategies.Cureus · 2026Review
- Effects ofAnimals : an open access journal from MDPI · 2026Article
- A modern reinterpretation of the "kidney governs bone" theory: systemic regulation of the neuro-endocrine-immune network via the brain-bone axis and traditional chinese medicine intervention strategies.Frontiers in pharmacology · 2026Review
- Osteosarcoma as a communication-driven disease: redefining tumor-bone signaling networks as therapeutic targets.Frontiers in oncology · 2026Review
- Single-cell transcriptome analysis profiles the enlarged subsets of myeloid-biased HSPCs with preleukemic characters in disuse osteoporosis mice.Cell & bioscience · 2025Article
- Hydrothermal Magnesium Alloy Extracts Modulate MicroRNA Expression in RAW264.7 Cells: Implications for Bone Remodeling.Journal of functional biomaterials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforming growth factor-beta (TGF-β), a cytokine embedded in the bone matrix, is released during bone resorption, influencing osteoclast differentiation and coupling factor production, which affect osteoblasts and osteocytes. This study investigates the role of TGF-β in bone remodeling using an in vitro model with calcium phosphate-coated plates covalently bonded to latent TGF-β (LTGF-β(+)-CaP plates). This model replicates the natural release of TGF-β and its effects on RAW264 macrophage-like cells, which differentiate into osteoclasts upon stimulation of RANKL. Cells cultured on LTGF-β(+)-CaP plates formed resorption pits and released TGF-β, upregulating osteoclast differentiation- and resorption-related genes during early differentiation. During the resorption phase, TGF-β-enhanced osteoblast activation and coupling factor expression supporting bone formation in surrounding cells. In osteocytes, it differentially regulated gene expression by upregulating osteoprotegerin and downregulating sclerostin, suggesting a dual role in remodeling. Our findings demonstrate that TGF-β plays a critical role in bone homeostasis by directly promoting osteoclast differentiation and resorption while indirectly facilitating osteoblast differentiation through coupling factors. These results provide insights into the dynamic interactions between osteoclasts, osteoblasts, and osteocytes, emphasizing TGF-β's role in linking bone resorption and formation. This study establishes a novel in vitro platform to examine TGF-β-mediated bone remodeling and its underlying molecular mechanisms. Furthermore, our model can be used to explore how TGF-β signaling affects cellular communication in the bone and may contribute to identifying new therapeutic targets for osteoporosis and other bone-resorptive disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.